# 2026-05064: DEA Bans Bromazolam: The Latest Sketchy Substance Gets Scheduled

2026-05064, Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I, is a Federal Register rule from Justice Department, Drug Enforcement Administration published 2026-03-16, effective 2026-03-16; PRIA reads it as touching household money (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2026-05064
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-05064
- Title: Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
- Type: Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 12504
- Published: 2026-03-16
- Effective: 2026-03-16
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

DEA Bans Bromazolam: The Latest Sketchy Substance Gets Scheduled

## Summary

Starting March 16, 2026, bromazolam—a drug that can be dangerous—is temporarily placed in Schedule I, the strictest drug category. This means anyone making, selling, or using bromazolam will face tough rules and penalties until March 16, 2028. The goal? To keep the public safe from harm while the government watches closely.

## Abstract

The Drug Enforcement Administration issues this temporary order to schedule 8-bromo-1-methyl-6-phenyl-4H- benzo[f][1,2,4]triazolo[4,3-a][l, 4]diazepine (commonly known as bromazolam), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers are possible, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing bromazolam in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle these substances.

## Effects PRIA read

- Bromazolam placed in Schedule I: cost, high. If you make, sell, possess, or use bromazolam, it is temporarily placed in Schedule I of the Controlled Substances Act from March 16, 2026 through March 16, 2028 (with a possible one-year extension). That means handling bromazolam without authorization may lead to criminal, civil, or administrative…
- DEA registration and compliance required: cost, medium. If you handle bromazolam (manufacture, distribute, import, export, research, chemical analysis, or possess), you must be registered with the DEA as of March 16, 2026 and follow Schedule I security, labeling, inventory, recordkeeping, reporting, and order-form rules. Current DEA registrants have 30…
- Manufacture limited to DEA-registered firms: cost, medium. Only DEA-registered manufacturers may manufacture bromazolam under an assigned manufacturing quota as of March 16, 2026. Manufacturing without DEA registration or outside assigned quota is unlawful and may lead to sanctions.
- Research continuation and 90-day rule: cost, low. If you are conducting research on bromazolam and are already registered to research another Schedule I substance on March 16, 2026, you may continue that bromazolam research if you submit a completed application to register or modify your registration within 90 calendar days after March 16, 2026. I…
- Surrender stocks if not registered: cost, medium. If you do not want or cannot obtain a Schedule I registration to handle bromazolam, you must surrender all quantities you currently hold as of March 16, 2026. Possession or handling after that date without authorization is unlawful and may lead to prosecution.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2026-05064 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)
- [2026-05064 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-16/pdf/2026-05064.pdf)

## Related
- [Previous: 2026-04990, Revocation of the 30-Day Notification Requirement Prior to Termination of Lease…](https://policyrisk.com/federal-register/2026-04990)
- [Next: 2026-05073, Fisheries of the Northeastern United States; Scup Fishery; 2026 Scup Winter I C…](https://policyrisk.com/federal-register/2026-05073)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-05064 (as of 2026-06-11).
